- "The case for using V503 is even stronger than the case for using Gardasil, which was already strong," Merck (MRK) says.
- V503 is an investigational HPV vaccine designed to provide protection against the four HPV strains Gardasil protects against, plus five additional cancer-causing types of the virus.
- Data from clinical trials — to be presented this week in Italy — appears to support the new vaccine's efficacy.
- MRK intends to seek approval for V503 by the end of the year.
- Leerink's 2018 sales projections (as cited by WSJ): V503 sales of $1.9B and Gardasil sales of $525M (down from $1.6B in 2012).
Merck to present data on new, improved HPV vaccine
Nov 3 2013, 21:09 ET